CCR Antagonist

CCR Antagonists (105):

Cat. No.	Product Name	Effect	Purity

HY-14882A

Cenicriviroc Mesylate	Antagonist	99.04%
Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

HY-122219

R243	Antagonist	98.04%
R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL₁/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects.

HY-15724

Vercirnon	Antagonist	98.26%
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively.

HY-103361

SB297006	Antagonist	99.88%
SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

HY-50669A

MK-0812 Succinate	Antagonist	99.90%
MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2.

HY-116835

BI-6901	Antagonist	99.94%
BI 6901 is a potent, selective CCR10 antagonist (pIC₅₀=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.

HY-103362

CCR2 antagonist 4 hydrochloride	Antagonist	99.86%
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM.

HY-50081

CCR2-RA-[R]	Antagonist	99.71%
CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC₅₀ of 103 nM.

HY-15450A

INCB 3284	Antagonist	99.30%
INCB 3284 is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.

HY-101908

BMS CCR2 22	Antagonist	99.87%
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC₅₀ of 5.1 nM) and potent functional antagonism (calcium flux IC₅₀ of 18 nM and chemotaxis IC₅₀ of 1 nM).

HY-100183

GSK2239633A	Antagonist	99.81%
GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [¹²⁵I]-TARC to human CCR4 with a pIC₅₀ of 7.96?±?0.11.

HY-108323

CCR2 antagonist 4	Antagonist	99.89%
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM.

HY-112792

CCR2 antagonist 1	Antagonist	98.00%
CCR2 antagonist 1 (compound 15a) is a high-affinity and long-residence-time CCR2 antagonist, with a K_i of 2.4 nM.

HY-P99697

Leronlimab	Antagonist	98.91%
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

HY-15724A

Vercirnon sodium	Antagonist	99.13%
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively.

HY-17377

Vicriviroc maleate	Antagonist	99.91%
Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a K_i of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC₉₀s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU?570).

HY-103364A

C-021 dihydrochloride	Antagonist	99.92%
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM.

HY-120588

BI 639667	Antagonist	99.47%
BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC₅₀ of 1.8 nM in Ca²⁺ flux assay.

HY-124759

CCR1 antagonist 9	Antagonist	99.93%
CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC₅₀ of 6.8 nM in calcium flux assay.

HY-144200

CCR8 antagonist 2	Antagonist	99.71%
CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220).

Name
Email *

	Sorry, but the email address you supplied was invalid.